Companies: 10,795·Total market cap: $144.5T
Silence Therapeutics plc

Silence Therapeutics plc

SLNNASDAQHealthcare● Active
$6.14
$-0.03(-0.49%)
Market Cap$290016441
P/E Ratio
52W High$8.4
52W Low$4.19
Overview

Silence Therapeutics plc (SLN) Stock Forecast & Analyst Price Target

Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.

sln · stock forecast · 5 analysts (3M) · FMP · updated Jun 8, 2026

Analyst Rating & Consensus

Based on 5 Wall Street analysts in the past 3 months

SellBuy

Buy

5 analysts

consensus

Rating Breakdown

Strong Buy
0
Buy
4
Hold
0
Sell
1
Strong Sell
0
Total: 5 · Buy rate: 80.0%

12-Month Price Target

High

$67.00

Consensus

$57.00

+828.3% upside

Low

$49.00

Median: $55 · Last Close: $6.14

The Silence Therapeutics plc (SLN) analyst consensus is Buy, based on ratings from 5 Wall Street analysts over the past 3 months. The average 12-month SLN price target is $57.00, representing +828.3% upside from the current price of $6.14.

12-Month Price Target Forecast

Historical closing prices + analyst 12-month price target forecast cone

Historical priceConsensus $57 (828.3%)

Consensus Target

$57.00

828.3% upside

High Target

$67

991.2%

Low Target

$49

698.0%

Current Price

$6.14

as of today

Based on analyst price targets, the SLN stock price prediction for the next 12 months ranges from $49 to $67. The consensus SLN price forecast of $57.00 implies 828.3% upside from the current price of $6.14.

Short-Term Price Prediction

Algorithmically generated · Updated daily

DatePredicted PriceChange
2026-06-09$6.041.60%

1-day model range: $5.98–$6.1. Peak: $6.1 (-1.60%).

Long-Term Stock Price Prediction

Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031

YearAvg PriceChange
2027$7+9.0%
2028$7+13.9%
2029$7+16.4%
2030$7+17.7%
2031+18.4%
Confidence:Medium

Stock Forecast Based on Technical Analysis

14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency

Market Sentiment

BEARISH

Based on 14 technical indicators

14%7%79%
2Buy
1Neutral
11Sell
RSI (14)48.8Neutral
MACDBEARISH

Refreshes daily from EOD close

Moving Averages · SLN · Jun 8, 2026

Simple Moving Average (SMA)
MA 5$6.39SELL
MA 10$6.57SELL
MA 20$6.54SELL
MA 50$6.65SELL
MA 100$6.07BUY
MA 200$6.03BUY
Current $SLN · Price above MA = BUY signal
Exponential Moving Average (EMA)
EMA 5$6.36SELL
EMA 10$6.46SELL
EMA 20$6.57SELL
EMA 50$6.55SELL
EMA 100$6.35SELL
EMA 200$6.34SELL
Current $SLN · Price above MA = BUY signal
How we calculate: Technical sentiment is derived from 14 indicators — SMA(5,10,20,50,100,200), EMA(5,10,20,50,100,200), RSI(14), and MACD(12,26,9) — calculated from historical EOD price data. BUY = current price above MA; SELL = below. 14 TA signals + historical EOD price data · Updated daily. Independent of analyst consensus data. Not investment advice.

Latest Analyst Ratings & Upgrades

Filter:
HC Wainwright & Co.2026-03-13
Maintains
BuyBuy
HC Wainwright & Co.2025-09-16
Maintains
BuyBuy
Chardan Capital2025-08-08
Maintains
BuyBuy
HC Wainwright & Co.2025-06-13
Maintains
BuyBuy
Chardan Capital2025-06-13
Maintains
BuyBuy
Morgan Stanley2025-05-09
Maintains
OverweightOverweight
Goldman Sachs2025-05-09
Maintains
SellSell
Chardan Capital2025-05-09
Maintains
BuyBuy
HC Wainwright & Co.2025-03-07
Maintains
BuyBuy
Morgan Stanley2025-03-05
Maintains
OverweightOverweight

Wall Street analysts have recently issued updated ratings on Silence Therapeutics plc (SLN) stock. Of the recent 53 rating actions, 0 were upgrades and 0 were downgrades. 5 analysts currently cover SLN.

Analyst Recommendation Trends

Buy ratings312
Hold ratings00
Sell ratings101

SLN analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 3 to 1 per month.

Financial Forecast: EPS & Revenue Estimates

Revenue This Year

$4M

↓ 74.4% YoY

Revenue Next Year

$6M

↑ 44.3% YoY

EPS This Year

$-0.54

EPS Next Year

$-0.58

↑ 7.4% YoY

EPS ForecastReported vs Estimated

Reported EPSHistorical estimateAnalyst forecast (future)

Analysts forecast SLN EPS of $-0.54 for the current fiscal year, based on estimates from 2 analysts. The SLN revenue forecast is $4M for the current year. These are analyst consensus estimates via FMP / S&P Global.

About Forecast & Price Prediction

The SLN stock forecast is supported by two independent data sources: analyst consensus ratings from 5 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus SLN price target is $57.00 (+828.3% upside), with an analyst consensus of Buy.

The SLN short-term stock prediction for tomorrow is $6.04 (-1.60%). The SLN stock price prediction for 2027 estimates an average of $7. The SLN stock prediction for 2030 projects a range of $6–$8.

Silence Therapeutics plc trades on NASDAQ under the ticker SLN. The SLN stock outlook for 2027 is broadly positive, supported by a Buy consensus among 80% of covering analysts.

FAQ answers synthesize analyst targets, estimates, and on-page model outputs where shown.

Frequently asked questions

SLN forecast · 8 questions

According to 5 Wall Street analysts, the average 12-month SLN price target is $57.00, with a high forecast of $67.00 and a low of $49.00. The median price target is shown in the chart above when available. This implies +828.3% potential upside from the current price of $6.14.

SLN price targetWhat is SLN price targetSLN analyst price targetSLN 12-month target

· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)

⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.